Fortification vs Supplementation: Public Health Pathways

Behind those figures sit millions of people whose bones, immune function, and seasonal mood are quietly shaped by a deficit they never name, and whose clinicians will rarely prescribe a serum test in the absence of symptoms. We have learned, over decades of public health work, that this is precisely the terrain where individual advice fails and population strategy must take its place. The question for policymakers, then, is not whether to intervene but along which pathway: should we engineer the food supply so that everyone ingests a baseline dose, or should we screen, identify, and supplement those at risk?

The two routes — mandatory or voluntary food fortification on one side, targeted or universal dietary supplementation on the other — are often presented as competitors. In practice, they are instruments that work at different scales, at different speeds, and against different failure modes. Comparing them honestly requires us to walk the regulatory maps, examine the safety thresholds EFSA has drawn for us, and look squarely at the prevalence data that justify either course of action in the first place.

The Regulatory Landscape: Mandatory vs. Voluntary Frameworks

Across the European Union, vitamin D food fortification lives inside a patchwork that no single diagram captures cleanly. The backbone is Regulation (EC) No 1925/2006 on the addition of vitamins and minerals to foods, which permits voluntary fortification across member states but leaves the question of whether, and how much, to each national authority. On top of that voluntary layer, a small group of countries has chosen to make fortification compulsory for specific vehicle foods.

Mandatory fortification narrows the gap between intention and intake — but only for those whose shopping baskets already include the chosen vehicle.

Finland adds vitamin D to homogenized skim milk; Sweden adds it to low-fat milk, fermented dairy products, plant-based drinks, and fat spreads; Belgium mandates it in margarine and selected fats; Poland follows a similar approach with margarine and fat spreads. Each of these decisions is the product of a national dietary survey, a political negotiation, and a cultural comfort level with state intervention in the food supply. The result is that a Swedish child drinking fortified oat milk and a Polish cook spreading fortified margarine on bread receive their baseline dose almost by default, while a peer in Portugal or Italy — where voluntary fortification dominates and intake relies on consumer choice — may or may not encounter fortified products at all.

The voluntary pathway, by contrast, hands the question to manufacturers and shoppers. A producer may add vitamin D to breakfast cereals, plant-based milks, or spreads, label the product accordingly, and trust that consumers seeking the nutrient will reach for it. This model respects consumer autonomy and allows rapid innovation in vehicle foods, but it leaves the population dose entirely dependent on market logic. In jurisdictions where voluntary fortification has been the only option for years, national surveys continue to show the same stubborn prevalence of low serum 25(OH)D — a quiet signal that the marketplace, left alone, does not deliver nutritional equity.

Population Reach and the Limits of Voluntary Supplementation

Supplementation programs — whether universal recommendations, targeted voucher schemes, or clinical prescribing — can move quickly. We have seen this during the COVID-19 era, when many European health agencies briefly issued blanket advice for daily vitamin D supplementation, and again each winter in countries like the UK where the Scientific Advisory Committee on Nutrition (SACN) recommends that everyone over four years old consider a daily 10 µg supplement during autumn and winter. Supplementation is the high-resolution tool: it reaches named individuals with measured doses, and it can be intensified for groups at particular risk, including infants, pregnant women, older adults in residential care, and people with darker skin or limited sun exposure.

The trouble is adherence. A daily pill, capsule, or drop is a behaviour, and behaviours erode. Long-term population adherence rates for voluntary supplementation vary enormously by socio-demographic strata, by country, and by whether the supplement is free at the point of delivery or paid for out of pocket. The European data we have suggest that even when knowledge of vitamin D deficiency is high, sustained daily use rarely breaks above a minority of the target population outside structured clinical settings. For public health planners, this is the central problem with a supplementation-first strategy: it is precise, but it leaks.

Food fortification, by contrast, is leaky in a different sense — it is impossible to target, because it reaches everyone who eats the vehicle food. A child who dislikes fortified milk, an adult who avoids margarine, or a household that cannot afford the fortified plant-based drink will miss the dose. But the average exposure across a population moves upward without anyone having to remember a daily tablet. In nutrition policy terms, fortification is a low-resolution, high-coverage instrument; supplementation is a high-resolution, low-coverage one. Neither alone is sufficient at the scale most European countries need.

Safety Thresholds: Navigating EFSA's Tolerable Upper Intake Levels

Any policy that adds vitamin D to the food supply must respect the safety ceiling, and in Europe that ceiling is set by the European Food Safety Authority. The EFSA Panel on Nutrition, Novel Foods and Food Allergens has established a Tolerable Upper Intake Level (UL) of 100 µg (4,000 IU) per day for adults, derived from a lowest-observed-adverse-effect-level (LOAEL) of 250 µg/day for persistent hypercalciuria, divided by an uncertainty factor of 2.5. For infants, the panel set a UL of 25 µg/day for those aged 0–6 months and 35 µg/day for those aged 6–12 months — figures that reflect both the smaller body mass and the narrower margin between adequate and excessive intake in early life.

These numbers shape every national conversation about mandatory fortification. A policy that adds vitamin D to fluid milk at 0.5–1 µg per 100 mL is contributing roughly 1–3 µg per typical daily consumption — orders of magnitude below the adult UL, and well within the infant UL for the small amounts a young child might drink. Even consumers who stack multiple fortified products in a single day rarely approach the ceiling under European fortification levels. The risk profile is fundamentally different from high-dose bolus supplementation, where single monthly or quarterly doses of 50,000 IU or more are sometimes prescribed clinically; those regimens carry a different pharmacokinetic shape and a different set of considerations around peak serum concentrations.

EFSA has also worked on the labeling mathematics of vitamin D equivalents. For calcidiol monohydrate — the 25-hydroxyvitamin D form sometimes used in fortified foods — a proposed conversion factor of 2.5 has been put forward so that labels can express a meaningful vitamin D3 equivalent. This kind of technical plumbing matters because it determines whether a fortified product genuinely closes a nutritional gap or only appears to do so on the package.

Safety is not a barrier to fortification — it is the architecture that makes large-scale fortification defensible.

Bridging the Deficiency Gap: Evidence from European Prevalence Data

The case for either pathway rests on the prevalence numbers, and those numbers are sobering. The 13 percent figure for serum 25(OH)D below 30 nmol/L reflects a strict deficiency threshold; the 40.4 percent figure below 50 nmol/L reflects a wider insufficiency band that public health agencies increasingly treat as the target. In a population of, say, 450 million Europeans, those percentages translate into tens of millions of people whose vitamin D status falls short of where the bone-health evidence suggests it should be.

It is important to say plainly what those numbers do and do not establish. They describe a population-level reality, not a verdict on any single policy. They do not, on their own, prove that mandatory fortification will eliminate severe deficiency; dietary habits, latitude, skin pigmentation, cultural clothing, and sun exposure all interact with intake, and a fortified food cannot compensate for a household that does not eat the chosen vehicle. They also do not prove that supplementation programs are failing — in many countries, targeted supplementation has demonstrably improved status in infants and pregnant women. What the prevalence data do establish is that voluntary, market-led approaches have not, on their own, closed the gap at population level. Something more systematic is required.

This is where the policy lens has to widen. The most successful national stories — Finland's long-running fortification programme, Sweden's expansion into plant-based drinks and fat spreads — share a feature: they combine a fortified vehicle layer with advice to supplement during winter, and they reassess the dose every few years against updated dietary surveys. That combination is not accidental; it is the logical answer to a problem that no single instrument can solve.

Strategic Trade-offs in National Nutrition Policy Design

Every ministry weighing mandatory fortification confronts the same set of trade-offs. The first is vehicle selection. Milk and dairy dominate in countries with strong dairy traditions, but plant-based drinks are increasingly important in markets where dairy consumption is falling, and fat spreads reach cooking habits that fluid milk does not. Sweden's choice to include plant-based drinks is, in effect, a bet on the future of where the dose will land. The second trade-off is dose: too little and the prevalence numbers do not move; too much and the program drifts toward the EFSA UL in high consumers. The third is the political economy — voluntary frameworks are easier to legislate because they require no compulsion on producers, but they also leave the public health outcome contingent on whether manufacturers choose to participate and on whether shoppers choose to buy.

We have spent enough years watching voluntary frameworks to know what they deliver in the absence of a clear national mandate: marginal improvements, persistent insufficiency, and a steady stream of policy reviews that recommend "considering mandatory options." The next logical move — and one that several European jurisdictions are now actively evaluating — is to treat fortification not as an optional market feature but as a piece of nutritional infrastructure, on the same footing as iodised salt or folic acid in flour.

That shift will not be painless. It will require updated maximum permitted levels for vitamin D across food categories, transparent labeling that respects the calcidiol conversion factor, and monitoring systems that can detect any drift toward the upper intake levels in heavy consumers. It will also require a continued role for supplementation, particularly for infants, pregnant women, older adults in care, and people whose cultural or medical circumstances make fortified foods unreliable. The honest policy position is not "either/or" but "both, in their right places."

A population dose in the food supply, layered with targeted supplementation for those who need more, is the architecture most likely to move the prevalence numbers.

If we take the 13 percent and 40.4 percent figures seriously — and we should, because they reflect real bones, real immune systems, and real winters — then the work ahead is not to choose between fortification and supplementation, but to design the combination that fits each country's dietary habits, regulatory appetite, and capacity to monitor. The systemic barrier is not technical. It is the willingness to treat vitamin D the way we already treat iodine: as a nutrient whose adequacy is a public responsibility, not a private purchase.